A Phase I Monocentric, Open-label, Randomized, Crossover Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers in Healthy Chinese Subjects
Latest Information Update: 27 Apr 2023
At a glance
- Drugs Sovleplenib (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Haematological malignancies; Idiopathic thrombocytopenic purpura; Lymphoma
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma
Most Recent Events
- 24 Apr 2023 Status changed to completed.
- 14 Apr 2022 New trial record